Anzeige
Mehr »
Montag, 24.08.2026 - Börsentäglich über 12.000 News
Geheime Kupferaktie: Kupfer auf Rekordhoch - steht dieser geheime Junior-Explorer jetzt vor einer Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D495 | ISIN: CA13765U2002 | Ticker-Symbol: 8CB0
Frankfurt
21.08.26 | 08:26
1,210 Euro
+3,42 % +0,040
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CANNARA BIOTECH INC Chart 1 Jahr
5-Tage-Chart
CANNARA BIOTECH INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2001,26023.08.

Aktuelle News zur CANNARA BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.08.Cannara Biotech Inc (2): Cannara arranges automatic share purchase plan1
22.07.Cannara Biotech Inc (2): Cannara gets OK from TSX for NCIB1
22.07.Cannara Biotech Inc.: Cannara Announces Normal Course Issuer Bid2
15.07.Cannara Q3 2026 slides: revenue climbs 16% as cash flow drops2
15.07.Cannara Biotech Reports Q3 2026 Results: Full Earnings Call Transcript1
CANNARA BIOTECH Aktie jetzt für 0€ handeln
15.07.Cannara Biotech Inc.: Cannara Reports Record Q3 Revenues and Continued Profitability Accompanied By Expanding National Distribution and Accelerated Capacity Expansion328Delivered strong Q3 financial results: Generated $31.8 million in total net revenues, $13.4 million in gross profit before fair value adjustments, or 42% of revenues, $8.5 million in adjusted EBITDA1...
► Artikel lesen
15.07.Cannara Biotech reports Q3 results3
15.07.Cannara Biotech Inc (2): Cannara Biotech, Curaleaf sign supply agreement2
15.07.Curaleaf Holdings Inc (2): Cannara Biotech, Curaleaf sign supply agreement2
14.07.Stocks in Play: Cannara Biotech Inc.1
08.07.Cannara Biotech Inc (2): Cannara Biotech to release Q3 results on July 151
02.07.Cannara Biotech Inc (2): Cannara obtains Canadian rights to Ampersand technology1
02.07.Cannara Biotech Inc.: Cannara Secures Exclusive Canadian Rights to Blue River's Ampersand Live Rosin Infusion Technology686MONTREAL, July 02, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. ("Cannara", the "Company", "us" or "we") (TSX: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade...
► Artikel lesen
07.05.Cannara Biotech Inc (2): Cannara Biotech closes Medican Organic acquisition1
14.04.Cannara Biotech GAAP EPS of $0.02, revenue of $27.1M1
14.04.Cannara Biotech Inc.: Cannara Reports Q2 Fiscal 2026 Results with Continued Profitability, Strong Operating Cash Flow and #1 Retail Market Share in Québec374Delivered strong Q2 financial results: Generated $27.2 million in total net revenues, $11.6 million in gross profit before fair value adjustments or 43% of revenues, $6.0 million in adjusted EBITDA1...
► Artikel lesen
07.04.Cannara Biotech Inc (2): Cannara Biotech to release fiscal Q2 results April 141
07.04.Stocks in Play: Cannara Biotech Inc.1
19.03.CEO Clips: Video - CEO Clips: Cannara Biotech Graduates to Toronto Stock Exchange424Vancouver, British Columbia--(Newsfile Corp. - March 19, 2026) - Cannara Biotech Inc. (TSX: LOVE) (OTCQX: LOVFF) (FSE: 8CB0) is a vertically integrated producer of affordable premium-grade cannabis...
► Artikel lesen
17.03.Toronto Stock Exchange: Cannara Biotech Inc. (LOVE) Opens the Market487Toronto, Ontario--(Newsfile Corp. - March 17, 2026) - Donald Olds, Lead Director and Chairman of the Audit and Governance Committee, Cannara Biotech Inc. ("Cannara" or the "Company") (TSX: LOVE)...
► Artikel lesen
Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1